Janssen Submits Marketing Authorisation Application for Daratumumab for European Patients With Heavily Pre-treated Multiple Myeloma

Janssen-Cilag International NV announced on September 9, 2015 it has submitted a new Marketing Authorisation Application to the European Medicines Agency (EMA) for daratumumab, an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma
Source: International Myeloma Foundation - Category: Hematology Source Type: news